anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Endogenous noncoding RNAs with a covalently closed loop are known as circular RNAs (circRNAs). Recently, published works have revealed that circRNAs, which act as microRNA sponges, are critical for the biological behavior of several kinds of malignancies, including tumor cell proliferation, apoptosis, invasion, and metastasis. Additionally, there is a significant correlation between circRNAs and tumor resistance, stage, prognosis, and size. At present, colorectal cancer (CRC) is one of the most serious malignant tumors for human health. CircRNAs could represent potential targets to use in the prevention, diagnosis, and therapy of CRC, according to many studies. To fully comprehend the role of circRNAs in the incidence and progression of CRC, this review outlines the regulatory role and mechanisms of circRNAs in CRC and assesses their potential relevance as diagnostic and treatment possibilities for CRC. Our goal is to offer meaningful biological information for clinical evaluation and decision-making process for CRC treatment.
The purpose of this study is to evaluate the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell (AlloMSC) transplantation in patients with refractory SLE. Patients with Lupus nephritis and refractory to corticosteroid or cyclophosphamide trials will be enrolled in this trial. The treatment intervention includes a 24 hour pretreatment with cyclophosphamide followed by AlloMSC transplantation. Patients will be admitted to the in-patient service for the 3-5 days for the transplant treatment and will be followed up in the outpatient clinic. All baseline lupus serology, renal function panels will be obtained at pre-treatment admission. Post-transplantation follow-up visits will be at monthly intervals for lupus serology and renal function tests, and every 3 months for analysis of T regulatory population. The transplanted patients will be evaluated by an integrated team of rheumatologists, hematologists and bone marrow transplant specialists every month for the entire duration of the trial (2 years) and every 6-12 months thereafter.
MicroRNAs (miRNAs) have been shown to play an important regulatory role in the process of pathogenic infection. However, the miRNAs that regulate the pathogenic process of G. parasuis and their functions are still unknown. Here, high-throughput sequencing was used to quantify the expression of miRNA in piglet lung tissue after G. parasuis XX0306 strain infection. A total of 25 differentially expressed microRNAs (DEmiRNAs) were identified. GO and KEGG pathway enrichment analysis showed that many of the functions of genes that may be regulated by DEmiRNA are related to inflammatory response and immune regulation. Further studies found that ssc-miR-135 may promote the expression of inflammatory factors through NF-κB signaling pathway. Whereas, ssc-miR-155-3p inhibited the inflammatory response induced by G. parasuis, and its regulatory mechanism remains to be further investigated. This study provides a valuable reference for revealing the regulatory effects of miRNAs on the pathogenesis of G. parasuis. DATA AVAILABILITY: The datasets generated during the current study are not publicly available due to this study is currently in the ongoing research stage, and some of the data cannot be made public sooner yet, but are available from the corresponding author on reasonable request.
The ability to detect low-level disease is key to our understanding of clonal heterogeneity in acute myeloid leukemia (AML) and residual disease that elude conventional assays and seed relapse. We developed a high-sensitivity next-generation sequencing (HS-NGS) clinical assay, able to reliably detect low levels (1 × 10-5) of FLT3-ITD, a frequent, therapeutically targetable and prognostically relevant mutation in AML. By applying this assay to 289 longitudinal samples from 62 patients at initial diagnosis and/or clinical follow-up (mean follow-up of 22 months), we reveal the frequent occurrence of FLT3-ITD subclones at diagnosis and demonstrate a significantly decreased relapse risk when FLT3-ITD is cleared after induction or thereafter. We perform pairwise sequencing of diagnosis and relapse samples from 23 patients to uncover more detailed patterns of FLT3-ITD clonal evolution at relapse than is detectable by less-sensitive assays. Finally, we show that rising ITD level during consecutive biopsies is a harbinger of impending relapse. Our findings corroborate the emerging clinical utility of high-sensitivity FLT3-ITD testing and expands our understanding of clonal dynamics in FLT3-ITD-positive AML.
The population of the study consisted of patients who were being treated in the general surgery clinic of the hospital, who met the sampling criteria, who were to undergo laparoscopic cholecystectomy, and who agreed to participate in the study. The sample size of the study was determined by the G\*Power 3.1.9.7 program. In the power analysis, when α =0.05, β=0.10, and 1-β =0.90, the sample size was determined as 50 people per group and a total of 100 people.
FIELD: organic synthesis. SUBSTANCE: novel derivatives of 1,4-dihydropyridine-3,5-dicarboxylic acid described by general formula I:   (I), wherein R 1  and R 3 , identical of different, are C 1 -C 8 -alkyl optionally substituted by C 1 -C 6 -alkoxy or hydroxyl, and R 2  is phenyl optionally substituted by halogen or cyano group. Preparation procedure I: benzylidene compound of formula II:   (II) is brought into interaction with aminocrotonic acid ester III:   (III), in which R 1  and R 2  are defined as indicated above and A is benzyl, in inert solvent, optionally in presence of base. Resulting intermediate is cleaved to liberate malic acid imide and desired product is isolated in the form of free base or salt. Preparation procedure II: benzylidene compound of formula IIa:   (IIa) is brought into interaction with aminocrotonic acid ester IIIa:   (IIIa), in which R 1 , R 2 , and A are defined as indicated above and synthesis is further continued as described for preparation procedure I. Compounds I are Ca(II) antagonists and show favorable effect on learning capacity and memory function. EFFECT: expanded assortment of useful biologically-active compounds. 5 cl, 2 dwg, 6 ex
Reformer Pilates were performed, 2 days a week, for 4 weeks, in a total of 8 sessions (45 minutes each). The exercises of the Reformer Pilates were given as individual sessions by the physiotherapist. Reformer Exercises were explained by the physiotherapist in detail to understand the movement and starting position correctly, and the participants were then asked to perform the movements.
Intravitreal injection of medicine has become the most common ocular procedure billed to Medicare. One of the main problems with this procedure is the postoperative discomfort due to the need to disinfect the eye with Povidone Iodine (PI). This disinfectant lowers the risk of endophthalmitis, but is very rough on the corneal epithelium, producing a type of corneal abrasion in many patients that is very uncomfortable in the first few days after injection. Many patients refuse the PI disinfection even though avoiding it increases the risk of endophthalmitis with the procedure. Recently another disinfectant has been FDA approved specifically for the eye to treat blepharitis and dry eye. Avenova (Av), a dilute solution of hypochlorous acid, is used several times a day for these conditions. Some practices have begun using it for PI sensitive patients before an intravitreal injection as it is FDA-approved for disinfecting peri-ocular structures. A recent in vitro study was published showing that it is superior to PI in kill times for bacteria cultured for endophthalmitis cases. Some physicians say it is superior to PI with respect to patient comfort, however, to date, there is little literature about its use for intravitreal injection. The objective of this study is to assess comfort levels between the two FDA-approved disinfection options and to compare disinfection rates between PI and Av. The hypothesis is that Av will be as effective or more effective in elimination ocular pathogens as PI and will be significantly more comfortable for patients.
OBJECTIVE: Mitochondrial fatty acid oxidation is a metabolic pathway whose dysregulation is recognized as a critical factor in various cancers, because it sustains cancer cell survival, proliferation, and metastasis. The acyl-CoA synthetase long-chain (ACSL) family is known to activate long-chain fatty acids, yet the specific role of ACSL3 in breast cancer has not been determined.
METHODS: We assessed the prognostic value of ACSL3 in breast cancer by using data from tumor samples. Gain-of-function and loss-of-function assays were also conducted to determine the roles and downstream regulatory mechanisms of ACSL3 in vitro and in vivo.
RESULTS: ACSL3 expression was notably downregulated in breast cancer tissues compared with normal tissues, and this phenotype correlated with improved survival outcomes. Functional experiments revealed that ACSL3 knockdown in breast cancer cells promoted cell proliferation, migration, and epithelial-mesenchymal transition. Mechanistically, ACSL3 was found to inhibit β-oxidation and the formation of associated byproducts, thereby suppressing malignant behavior in breast cancer. Importantly, ACSL3 was found to interact with YES proto-oncogene 1, a member of the Src family of tyrosine kinases, and to suppress its activation through phosphorylation at Tyr419. The decrease in activated YES1 consequently inhibited YAP1 nuclear colocalization and transcriptional complex formation, and the expression of its downstream genes in breast cancer cell nuclei.
CONCLUSIONS: ACSL3 suppresses breast cancer progression by impeding lipid metabolism reprogramming, and inhibiting malignant behaviors through phospho-YES1 mediated inhibition of YAP1 and its downstream pathways. These findings suggest that ACSL3 may serve as a potential biomarker and target for comprehensive therapeutic strategies for breast cancer.
Base changes in the chronic infusion rate on persistence, recurrence, or worsening of the patient’s symptoms of pulmonary hypertension and the occurrence of adverse events due to excessive doses of epoprostenol for injection. In general, expect increases in dose from the initial chronic dose.

Consider increments in dose if symptoms of pulmonary hypertension persist or recur. Adjust the infusion by 1- to 2-ng/kg/min increments at intervals sufficient to allow assessment of clinical response; these intervals should be at least 15 minutes. In clinical trials, incremental increases in dose occurred at intervals of 24 to 48 hours or longer. Following establishment of new chronic infusion rate, observe the patient, and monitor standing and supine blood pressure and heart rate for several hours to ensure that the new dose is tolerated.

During chronic infusion, the occurrence of dose-limiting pharmacological events may necessitate a decrease in infusion rate, but the adverse event may occasionally resolve without dosage adjustment. Make dosage decreases gradually in 2-ng/kg/min decrements every 15 minutes or longer until the dose-limiting effects resolve [see Adverse Reactions (6.1 and 6.2)]. Avoid abrupt withdrawal of epoprostenol for injection or sudden large reductions in infusion rates. Except in life-threatening situations (e.g., unconsciousness, collapse, etc.), infusion rates of epoprostenol for injection should be adjusted only under the direction of a physician.

In patients receiving lung transplants, doses of epoprostenol were tapered after the initiation of cardiopulmonary bypass.
Nanoparticles and formulations for non-surgical sterilization are disclosed herein. The nanoparticles for non-surgical sterilization contains a cage, such as a zeolitic imidazolate framework ("ZIF"), a surface modifying agent, a targeting ligand, and an active agent. The surface modifying agent is attached to the outer surface of the cage and the targeting ligand is exposed to the surrounding environment. The active agent is encapsulated in the cage. The targeting ligand binds to a reproductive hormone or a receptor of a reproductive hormone. The active agents can be a ribosome inactivating protein, an apoptosis inducer, a hormone, a receptor ligand, or a nucleic acid, or a combination thereof, that inactivates the ovaries or testes. Uses for the nanoparticles and formulations incorporating the nanoparticles for sterilizing a subject in need thereof are also disclosed.
The invention belongs to the field of biochemistry, and particularly relates to an RNA inhibitor for inhibiting hepatitis B virus gene expression and application thereof. The RNA inhibitor is formed by a positive-sense strand and an antisense strand through base pairing, and at least 85% of bases between the positive-sense strand and the antisense strand are complementary; -OH at the 2'site of partial or all nucleotide glycosyls is substituted by fluorine or methoxyl, and phosphate among at least three continuous nucleotides at the tail end is sulfated. The structure of the RNA inhibitor also contains 5'MVIP and 3'MVIP, so that the RNA inhibitor has specific liver targeting. The RNA inhibitor provided by the invention has the efficacy which is not possessed by the current clinical first-line hepatitis B treatment medicine, and can continuously and efficiently inhibit the synthesis of HBV surface antigen HBsAg and the generation of surface antibody HBsAb. The RNA inhibitor disclosed by the invention has a remarkable inhibition effect on the most common A, B, C and D types of HBV. The RNA inhibitor is combined with a nucleoside analogue or interferon for use, so that the hepatitis B can be functionally cured.
PCT No. PCT/JP92/01642 Sec. 371 Date Jun. 17, 1994 Sec. 102(e) Date Jun. 17, 1994 PCT Filed Dec. 17, 1992 PCT Pub. No. WO93/12798 PCT Pub. Date Jul. 8, 1993.The present invention provides a method for using the anti-obesity agent comprising 4-cholesten-3-one represented by the following formula:   <IMAGE>   as an effective component. The anti-obesity agent of the present invention is useful because of inhibition effect of body weight increase and body fat accumulation. The present invention also provides a medicinal composition comprising 4-cholesten-3-one as an effective component and a pharmaceutically acceptable excipient as well as methods for preventing and treating obesity comprising administering an effective amount of 4-cholesten-3-one to a person.
PURPOSE: The purpose of this study was to explore the characteristics of external auditory canal cholesteatoma (EACC) among children and to describe its radiological findings on high-resolution computed tomography (CT) of the temporal bone in order to improve the diagnostic accuracy of primary EACC.
METHODS: The clinical records and CT imaging features of 44 patients who were diagnosed with EACC between January 2017 and May 2022 at Shenzhen Children's Hospital were retrospectively reviewed. Clinical features, including external auditory canal wall findings, hearing damage, symptoms and physical examination findings, were analysed against the level of lesion involvement. The correlation between different types of EACC and the incidence of different clinical symptoms was analysed, and the degree of hearing impairment and the rate of bone wall destruction were examined using CT.
RESULTS: The mean age at EACC onset was 9.02 ± 3.15 years, and the mean age at onset for EACC involving the right ear was older than that of EACC involving the left ear (P < 0.05). There were 44 patients (46 ears), including 10 ears with type I EACC, 23 ears with type II EACC, and 13 ears with type III EACC. Conductive hearing loss was the main type of hearing impairment observed among EACC patients. There were differences in types I, II and III EACC in terms of hearing impairment; specifically, there was a significant difference in moderate hearing impairment between type II and type III EACC patients (P < 0.05). The four most common symptoms were otorrhea, otalgia, itching and bleeding. The incidence of itching symptoms was greater in type I EACC than the incidence of otorrhea, and the incidence of otorrhea symptoms in type II and type III EACC was significantly greater than that in type I EACC(P < 0.05). There were no significant differences in the fracture rates of the anterior, posterior, superior or inferior walls of the external auditory canal within or between type II and type III EACC patients (P > 0.05). The failure rate of scute damage was significantly higher in type III EACC patients than in type II EACC patients (P < 0.05).
CONCLUSION: The presence of otorrhea and hearing loss as well as the identification of granulation tissue during otoscopy suggest the need for a temporal bone CT scan. This imaging modality can aid in the early detection and accurate classification of EACC, thereby guiding the selection of appropriate surgical interventions and greatly assisting in preventing further progression of hearing impairment.
Riboflavin is produced by propagating at temperatures of 15-40 DEG C. an active culture of Eremothecium Ashbyii in an aqueous nutrient mash containing protein containing materials and metabolizable carbohydrates or lipoids with constant agitation and aeration throughout the mash, the initial pH being between 4.5-9.1.  The process may be carried out at either atmospheric or super - atmospheric pressure.  Materials mentioned as suitable to be included in the mash include milk, whey, steep water, molasses and mashes made from water and cereal grains, oil meals, seeds from leguminous plants such as peas, soya beans or field beans. Lipoids mentioned include peptone or egg albumin, corn oil, lecithin, olive oil, peanut oil and cocoa butter.  Waste protein materials mentioned include tankage fish meal, meat scrap, untreated hide scrap and dried yeast. Carbohydrates mentioned include glucose, sacrose and mannose.  After the fermentation is over (50-90 hours), the product is concentrated by evaporation, or spray dried.  Examples are given of the process of the invention, using as the starting materials (1)-(4) thin grain fermentation residue; (5) glucose and thin residue from whisky distillation; (6) corn steep water and thin grain alcohol; (7) thin grain alcohol residue with various carbohydrates added; (8) mineral salts, lipoids and peptone or egg albumen.  Reference has been directed by the Comptroller to Specification 594,015.
Is there anything more controversial than homosexuality and its origin? Despite the evidence that bisexual or homosexual behaviour is largely practiced in nature, in close to 1,500 species no less, ranging from primates to gut worms \[4\], the majority of religious authorities, as well as some political institutions, consider sex with people of the same gender unnatural. Confusion between the level of biological evidence with the level of moral and metaphysic aspects has been and is, unfortunately, frequent. However, we can immediately answer the question in the title: yes, definitively, homosexuality is natural. Would this suggest that biology plays a major role in homosexuality? Probably, but not necessarily. While some people believe that sexual orientation is innate and fixed, for others, sexual orientation may develop across a person's lifetime. The words of John Bancroft, which conclude this Controversy, clarify several aspects of these opposite interpretations 5.

Controversy is limited to male homosexuality (MH) for three reasons: (i) homosexuality in males (HM) is more common than homosexual females; (ii) MH is much more scientifically studied than female homosexuality; and (iii) moral and religious concerns seem much more concentrated on HM than on lesbian behaviour. An impressive amount of empirical data suggests that biology is an important regulator of both heterosexual and homosexual behaviours. Evidence has been produced showing the importance of genetic, autoimmune, and neurohormonal factors in the development of sexual orientation. Criticizing methods and findings produced in the field of biology of sexual orientation 6.

Mustanski et al. admit that genetic research using family and twin methodologies has produced consistent evidence that genes influence sexual orientation, but molecular research has not yet produced compelling evidence for specific genes 7. Although it has been well established that older brothers increase the odds of homosexuality in men, the route by which this occurs has not been fully resolved. Even the robust and elegant evidence solving the Darwinian paradox (how an antireproductive gene may survive?) produced by Camperio-Ciani need to be confirmed in larger samples. This author discusses here the fertility advantages of carrying the "gene" of HM, using arguments similar to that known for the thalassemia trait, which may confer a degree of protection against malaria, prevalent in the regions where the trait is common, thus conferring a selective survival advantage on carriers and perpetuating the mutation
FIELD: medicine. SUBSTANCE: essence of new method resides in determining degree of risk of development of late toxicosis during period of pregnancy, including foodstuffs having minimum allergogenic potential, putting on diet for each week according to "rotation" principle, including foods containing obligate allergens twice or thrice a week, and excluding foodstuffs characterized by high sensibilizing activity. Whenever initial symptoms of pretoxicosis are revealed, membrane stabilizing vitamins are perorally administered. In the last trimester, antianemic ferrotherapy is to be carried out by administering tardiferon. New method further prescribes determination of level of P-proteins in blood plasma and daily screening urine for membranolysis of renal cytomembranes. EFFECT: rate of late gestational toxicoses and number of cases of severe nephropathies reduced three times, diminished catabolism of renal cytomembranes in dynamic progress, premature births curtailed 2.5 times, and number of cases of infectious diseases in pueperae and frequency of infectious diseases in post-operative period radically decreased.
FIELD: biotechnology. SUBSTANCE: method involves modifications in composition of microflora, ratio of cultures and in accumulation their biomass. Concentrated protein hydrolyzate of skimmed milk is used as fodder substrate and as drying medium simultaneously. Said hydrolyzate is prepared by hydrolysis of protosubtiline having activity 70-80 units at dose 0.020-0.030 mass % , the process is carried out within 6-8 h. Bifidobacteria and mesophile lactic acid streptococcus (Lactococcus lactis sulsp. diacetillactis) are accumulated together, the process is carried out on nutrient medium at 39-41 C, initial dose of components is 8-10 mass % and 0.01-0.1 mass % respectively. Nutrient medium contains, mass %: glucose 0.4-0.5, sodium acetate 0.2-0.3, potassium hydrophosphate or potassium dihydrophosphate 0.1-0.2, corn extract 1.8-2.0, sodium citrate 0.4-0.5, ferric sulfate 0/03-0.05. Inoculate of bifidobacteria and lactic acid streptococcus or cell biomass together with separately prepared ferment of Bacillus acidophilus are added into protein hydrolyzate at ratio 5-20 mass % and 1-5 mass %, said process is followed by spray drying. Mentioned above hydrolyzate is condensed till dry substance content in it is 38-42%. EFFECT: increases biological value of the product, decreases its cost.